Geron Corporation
GERNHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Geron Corporation (GERN) is listed under Biotechnology. With a market capitalization of $719.6M, it sits in small-cap territory. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Market Cap
$719.6M
Beta
0.61
P/E (TTM)
—
P/E (Fwd)
28.00
EPS (TTM)
$-0.11
EPS (Fwd)
$0.04
ROE
-28.3%
ROA
-4.1%
Cash
$300.8M
Total Debt
$122.1M
Free CF
-$78.4M
52W Change
-12.5%
Annual Financials
Cash vs Debt
Where GERN stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, GERN finished 16.20% below its 150-day moving average ($1.42) and 17.36% below its 200-day moving average ($1.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GERN overbought or oversold?
At the October 15, 2026 close, GERN's RSI(14) was 26.7, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Geron Corporation holds $300.8M in cash against $122.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$78.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -28.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $596K (2022) to $183.9M (2025), reflecting a 30753% increase over the period.
GERN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GERN.